Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 6/20 | 0.58 |
| ▸ | DPP4 | P27487 | 3/20 | 0.58 |
| ▸ | FAP | Q12884 | 3/20 | 0.58 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5672334 | 0.85 | KMT2A (0.50) | PREPDPP4FAPRAB9AKMT2A | |
| SCHEMBL5673598 | 0.84 | L3MBTL1 (0.55) | PREPDPP4SMN1; SMN2CHRNA7RAB9A | |
| SCHEMBL5672207 | 0.82 | PREP (0.65) | PREP | |
| SCHEMBL5673611 | 0.82 | CHRM1 (0.47) | PREPFAPCHRNA7HTR3ADPP8 | |
| SCHEMBL18848739 | 0.78 | KDM1A (0.51) | PREPDPP4FAPDPP7DPP8 | |
| SCHEMBL4030570 | 0.76 | CHRNA7 (0.60) | CHRNA7HTR3A | |
| SCHEMBL22811348 | 0.76 | PREP (0.69) | PREPDPP4FAPDPP7SMN1; SMN2 | |
| SCHEMBL22209470 | 0.76 | PREP (0.69) | PREPDPP4FAPDPP7SMN1; SMN2 | |
| SCHEMBL8250328 | 0.74 | PREP (1.00) | PREPDPP4FAPDPP7DPP8 | |
| SCHEMBL1786176 | 0.73 | CHRNA7 (0.54) | SMN1; SMN2CHRNA7HTR3ARAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001902-B2 | 4-(2 phenylthiazol-5-yl)-1, 4-diazabicyclo-[3.2.2]nonane derivatives, preparation and therapeutic use thereof | SANOTL-AVENTIS (FR) | 2006-02-21 | — | — | US | disclosed |
| EP-1289987-B1 | 4-(2-PHENYLTHIAZOL-5-YL)-1,4-DIAZABICYCLO- 3.2.2]NONANE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SYNTHELABO (FR) | 2004-05-19 | — | — | EP | disclosed |
| US-20040029884-A1 | 4-(2 phenylthiazol-5-yl)-1, 4-diazabicyclo-[3.2.2]nonane deirvatives, preparation and therapeutic use thereof | SANOFI (FR) | 2004-02-12 | — | — | US | disclosed |
| EP-1289987-A1 | 4-(2-PHENYLTHIAZOL-5-YL)-1,4-DIAZABICYCLO- 3.2.2]NONANE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001092260-A1 | 4-(2-PHENYLTHIAZOL-5-YL)-1,4-DIAZABICYCLO-[3.2.2]NONANE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029884-A1 | 4-(2 phenylthiazol-5-yl)-1, 4-diazabicyclo-[3.2.2]nonane deirvatives, preparation and therapeutic use thereof | CBR1, FPR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PREP 2755/4885DPP4 158/4885FAP 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.